Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Technical Pointers on Drug Manufacturers – Major Stocks — Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and AstraZeneca

[Accesswire] – NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Park Lane Advisor has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline … Read more on this. Bristol-Myers Squibb Company (BMY) , valued at $101.48B, started the session at $61.87. Today, shares have traded between $60.52 and $62.36 per share with a one year range of $51.82 to $70.87. BMY shares are currently priced at 26.79x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -6.38x earnings multiple. The company pays shareholders $1.52 per share annually in dividends, yielding 2.45%. According to a consensus of 13 analysts, the earnings estimate of $0.65 per share would be $0.06 worse than the year-ago quarter and a $0.06 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $2.32, which would be a $0.31 improvement when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.15 Billion. If reported, that would be a 2.72% increase over the year-ago quarter. In terms of ratings, Berenberg upgraded BMY from Hold to Buy (Jan 22, 2016). Previously, Piper Jaffray upgraded BMY from Underweight to Neutral. The average price target for BMY shares by the analysts covering the stock is $74.30, which is 20.09% above where the stock opened this morning. See more in (NYSE:BMY) Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD